Literature DB >> 10817499

Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR.

J Bojunga1, S Röddiger, M Stanisch, K Kusterer, R Kurek, H Renneberg, S Adams, E Lindhorst, K H Usadel, P M Schumm-Draeger.   

Abstract

The sensitive detection of circulating tumour cells in patients with differentiated thyroid cancer may precede the detection of relapse by other diagnostic studies--such as serum thyroglobulin-and thus may have important therapeutic and prognostic implications. We performed reverse transcription-polymerase chain reaction (RT-PCR) on blood samples from patients diagnosed with thyroid disease using two different RT-PCR sensitivities. Additionally, tissue specificity of TG mRNA-expression was determined using RNA extracts from 27 different human tissues. The lower limit of detection was 50-100 TG mRNA producing cells/ml blood using a 'normal' RT-PCR sensitivity and 10-20 cells/ml blood using a 'high' sensitivity. With the normal sensitivity TG mRNA was detected in 9/13 patients with thyroid cancer and metastasis, 63/137 patients with a history of thyroid cancer and no metastasis, 21/85 with non-malignant thyroid disease and 9/50 controls. With the high sensitivity TG mRNA was detected in 11/13 patients with thyroid cancer and metastasis, 111/137 patients with a history of thyroid cancer and no metastasis, 61/85 with non-malignant thyroid disease and 41/50 controls. Interestingly, using the normal RT-PCR sensitivity TG mRNA transcripts are specific for thyroid tissue and detectable in the peripheral blood of controls and patients with thyroid disease, which correlates with a diagnosis of metastasized thyroid cancer. However, with a high RT-PCR sensitivity, TG mRNA expression was found not to be specific for thyroid tissue and was not correlated with a diagnosis of thyroid cancer in patients. As a consequence, to date TG mRNA detected by RT-PCR in the peripheral blood cannot be recommended as a tumour marker superior to TG serum-level.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817499      PMCID: PMC2374521          DOI: 10.1054/bjoc.1999.1209

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

Review 1.  The diagnosis of recurrent thyroid cancer--a new approach.

Authors:  R S Haber
Journal:  J Clin Endocrinol Metab       Date:  1998-12       Impact factor: 5.958

Review 2.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

3.  Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment.

Authors:  L E Sanders; B Cady
Journal:  Arch Surg       Date:  1998-04

4.  Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas.

Authors:  A J Herle; R P Uller
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

5.  Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease.

Authors:  G Tallini; R A Ghossein; J Emanuel; J Gill; B Kinder; A B Dimich; J Costa; R Robbins; G N Burrow; J Rosai
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

6.  Prognostic factors in differentiated thyroid carcinoma: a multivariate analysis of 234 consecutive patients.

Authors:  R Bellantone; C P Lombardi; M Boscherini; A Ferrante; M Raffaelli; F Rubino; M Bossola; F Crucitti
Journal:  J Surg Oncol       Date:  1998-08       Impact factor: 3.454

7.  Transcription of thyroid autoantigens in non-expressing tissues.

Authors:  G Aust; M Crisp; E Bösenberg; M Ludgate; A P Weetman; R Paschke
Journal:  Exp Clin Endocrinol Diabetes       Date:  1998       Impact factor: 2.949

8.  Thyroglobulin in benign and malignant thyroid disease.

Authors:  P L Gerfo; T Colacchio; D Colacchio; C Feind
Journal:  JAMA       Date:  1979-03-02       Impact factor: 56.272

9.  Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.

Authors:  K C Loh; F S Greenspan; L Gee; T R Miller; P P Yeo
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

10.  Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood.

Authors:  M D Ringel; P W Ladenson; M A Levine
Journal:  J Clin Endocrinol Metab       Date:  1998-12       Impact factor: 5.958

View more
  9 in total

1.  Human kallikrein 2 (hK2) mRNA in peripheral blood of patients with thyroid cancer: a novel molecular marker?

Authors:  Sandra J Roddiger; Heiner Renneberg; Thomas Martin; Ulf W Tunn; Nikolaos Zamboglou; Ralf Kurek
Journal:  J Cancer Res Clin Oncol       Date:  2003-02-12       Impact factor: 4.553

2.  Detection of lymph node metastases of papillary thyroid cancer-comparison of the results of histopathology, immunohistochemistry and reverse transcription-polymerase chain reaction-a preliminary report.

Authors:  L Pomorski; Krzysztof Kaczka; S Piaskowski; I Wójcik; P Rieske; M Matejkowska; K Kuzdak
Journal:  Langenbecks Arch Surg       Date:  2005-01-08       Impact factor: 3.445

3.  Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer.

Authors:  D Grammatopoulos; Y Elliott; S C Smith; I Brown; R J Grieve; E W Hillhouse; M A Levine; M D Ringel
Journal:  Mol Pathol       Date:  2003-06

4.  Evaluation of proopiomelanocortin mRNA in the peripheral blood from patients with Cushing's syndrome of different origin.

Authors:  S Bondioni; G Mantovani; N Polentarutti; B Ambrosi; P Loli; E Peverelli; A G Lania; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

5.  Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma.

Authors:  J Bojunga; C Dragan; P M Schumm-Draeger; K H Usadel; K Kusterer
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

6.  Quantitative measurement of thyroglobulin mRNA in peripheral blood of patients after total thyroidectomy.

Authors:  T Takano; A Miyauchi; H Yoshida; Y Hasegawa; K Kuma; N Amino
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

7.  Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.

Authors:  E Hesse; P B Musholt; E Potter; T Petrich; M Wehmeier; R von Wasielewski; R Lichtinghagen; T J Musholt
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

8.  One-step nucleic acid amplification testing in medullary thyroid cancer lymph nodes: a case series.

Authors:  Krzysztof Kaczka; Wojciech Fendler; Maciej Borowiec; Wojciech Młynarski; Katarzyna Paduszynska; Anna Grzegory; Lech Pomorski
Journal:  Arch Med Sci       Date:  2015-03-14       Impact factor: 3.318

Review 9.  Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it?

Authors:  F A Verburg; C J M Lips; E G W M Lentjes; J M H de Klerk
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.